October 02, 2014 12:33 AM ET


Company Overview of Cima Labs Inc.

Company Overview

Cima Labs Inc. engages in the research and development (R&D), formulation, manufacturing, and packaging of drug delivery technologies for pharmaceutical companies in the United States and internationally. The company specializes in orally disintegrating tablet (ODT), oral trans-mucosal (OTM), and oral powder drug delivery technologies. It offers ODTs, such as OraSolv, a technology that delivers taste-masked drug micro particles through a formulation, which enhances tablet disintegration; DuraSolv, a technology, which produces an ODT that combines taste-masked active drug ingredients with or without a low effervescence system; and Lyoc, a technology that lyophilizes or freeze-dries an aqueous...

7325 Aspen Lane

Brooklyn Park, MN 55428

United States

Founded in 1986

273 Employees





Key Executives for Cima Labs Inc.

Vice President of Drug Delivery Technologies
Senior Director of Regulatory Affairs & Project Management
Senior Director of Analytical Development
Compensation as of Fiscal Year 2014.

Cima Labs Inc. Key Developments

CIMA LABS INC. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013

CIMA LABS INC. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.

Mylan, Inc. Enters into Settlement Agreement with Cima Labs, Inc. and Shionogi Inc

Mylan, Inc. announced that it has entered into a settlement agreement with Shionogi Inc. and Cima Labs, Inc. that will resolve patent litigation related to Prednisolone Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg. Prednisolone Sodium Phosphate ODT is the generic version of Shionogi's Orapred ODT(R), which is indicated for the treatment of certain pulmonary diseases such as asthma. Additionally, the product is indicated for the control of certain severe or incapacitating allergic conditions, such as atopic dermatitis, and seasonal and perennial allergic rhinitis, that are intractable to adequate trials of conventional treatment. According to the terms of the settlement, Mylan will be licensed to sell its Prednisolone Sodium Phosphate ODT product on April 1, 2014, or earlier under certain circumstances. Pursuant to the agreement, pending litigation will be dismissed. Other details of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Similar Private Companies By Industry

Company Name Region
Carepeutics, Inc. United States
Royer Biomedical, Inc. United States
PharmaPrint Inc. United States
Antrim Corporation United States
Osprey Pharmaceuticals USA, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cima Labs Inc., please visit www.cimalabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.